These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2694530)

  • 1. Muscarinic agonists for senile dementia: past experience and future trends.
    Gray JA; Enz A; Spiegel R
    Trends Pharmacol Sci; 1989 Dec; Suppl():85-8. PubMed ID: 2694530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
    Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT).
    Wettstein A; Spiegel R
    Psychopharmacology (Berl); 1984; 84(4):572-3. PubMed ID: 6441959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
    Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
    Malviya M; Kumar YC; Mythri RB; Venkateshappa C; Subhash MN; Rangappa KS
    Bioorg Med Chem; 2009 Aug; 17(15):5526-34. PubMed ID: 19595599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain.
    Raiteri M; Leardi R; Marchi M
    J Pharmacol Exp Ther; 1984 Jan; 228(1):209-14. PubMed ID: 6141277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental pharmacology of Alzheimer disease.
    Greenwald BS; Davis KL
    Adv Neurol; 1983; 38():87-102. PubMed ID: 6137135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cholinergic treatment strategies in Alzheimer's disease].
    Kurz A; Rüster P; Romero B; Zimmer R
    Nervenarzt; 1986 Oct; 57(10):558-69. PubMed ID: 3785472
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.
    Ladner CJ; Lee JM
    Exp Neurol; 1999 Aug; 158(2):451-8. PubMed ID: 10415152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of muscarinic agonists in Alzheimer's disease.
    Avery EE; Baker LD; Asthana S
    Drugs Aging; 1997 Dec; 11(6):450-9. PubMed ID: 9413702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscarinic receptor 1 agonist activity of novel N-arylthioureas substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
    Malviya M; Kumar YC; Asha D; Chandra JN; Subhash MN; Rangappa KS
    Bioorg Med Chem; 2008 Aug; 16(15):7095-101. PubMed ID: 18640043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional differences in receptor reserve for analogs of oxotremorine in vivo: implications for development of selective muscarinic agonists.
    Ringdahl B; Roch M; Jenden DJ
    J Pharmacol Exp Ther; 1987 Aug; 242(2):464-71. PubMed ID: 3612545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
    Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term exposure to somatostatin or muscarinic agonists reduce acetylcholine-induced 3H-MPP+ release from bovine adrenal medullary cells.
    Ribeiro L; Martel F; Azevedo I
    J Biomed Sci; 2007 May; 14(3):347-55. PubMed ID: 17225960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in medicinal chemistry of novel selective muscarinic agonists.
    Fisher A; Karton Y; Heldman E; Gurwitz D; Haring R; Meshulam H; Brandeis R; Pittel Z; Segall Y; Marciano D
    Drug Des Discov; 1993; 9(3-4):221-35. PubMed ID: 8400004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
    Vamvakidès A
    Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic drugs, affective disorders and dementia: problems of clinical research.
    Spiegel R
    Acta Psychiatr Scand Suppl; 1991; 366():66-9. PubMed ID: 1897378
    [No Abstract]   [Full Text] [Related]  

  • 18. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.
    Bruno G; Mohr E; Gillespie M; Fedio P; Chase TN
    Arch Neurol; 1986 Jul; 43(7):659-61. PubMed ID: 3524514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
    Mouradian MM; Mohr E; Williams JA; Chase TN
    Neurology; 1988 Apr; 38(4):606-8. PubMed ID: 3281057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease.
    Davis R; Raby C; Callahan MJ; Lipinski W; Schwarz R; Dudley DT; Lauffer D; Reece P; Jaen J; Tecle H
    Prog Brain Res; 1993; 98():439-45. PubMed ID: 8248534
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.